+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pricing of pharmaceuticals. Assessing the pricing potential by a pricing matrix model



Pricing of pharmaceuticals. Assessing the pricing potential by a pricing matrix model



European Journal of Health Economics 5(2): 110-115



Pricing and reimbursement of new pharmaceuticals have been based until recently on the traditional clinical trial outcomes (efficacy, safety, and quality parameters) used for registration. Now we can distinguish various additional data requirements which relate to the use of the drug in real daily practice. The most important new data requirements are effectiveness, cost-effectiveness, and budgetary impact. A main question is how much the impact is of the various types of data in the pricing and reimbursement process. The objective of this contribution is to present a method for quantifying this type of uncertainty in order to develop a more solid pricing and reimbursement strategy for a new innovative drug. The concepts are illustrated for a new hypothetical antidepressant drug in The Netherlands. This method is based on the analytic hierarchy process (AHP) concept which measures decision makers' preferences for the critical success factors. This study shows that the AHP concept may be applied to the pricing and reimbursement environment. The method may be used to assess the pricing potential of a new drug, considering the various data requirements in the reimbursement process.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 050009747

Download citation: RISBibTeXText

PMID: 15452745

DOI: 10.1007/s10198-003-0209-y


Related references

Assessing the financial performance of forestry-related investment vehicles: capital asset pricing model vs. arbitrage pricing theory. American Journal of Agricultural Economics 83(3): 7-28, 2001

Differential Pricing For Pharmaceuticals: Overview Of A Widely Debated Pricing Concept And Key Challenges. Value in Health 18(7): A526, 2015

The capital-asset-pricing model and arbitrage pricing theory: A unification. Proceedings of the National Academy of Sciences of the United States of America 94(8): 4229-4232, 1997

Pricing health services: verification of a monopoly pricing model for dentistry. Journal of Human Resources 13(3): 402-415, 1978

From a bundled energy-capacity pricing model to an energycapacityancillary services pricing model. Energy Policy 36(8): 2878-2886, 2008

Non-monotonic pricing kernel and an extended class of mixture of distributions for option pricing. Review of Derivatives Research 17(2): 241-259, 2014

From a cancer drug fund to value based pricing of drugs: Such pricing may be hard to implement and may not add value. BMJ 341(7770): 412-413, 2010

Pricing myopia: do leading companies capture the full value of their pricing strategies?. Management Decision 52(1): 159-178, 2014

Pricing hospital care: Global budgets and marginal pricing strategies. Health Policy 119(8): 1111-1118, 2016

Pork pricing systems: the importance and economic impact of formula pricing. Working Paper Series, Studies of the Organization and Control of the US Food System (WP-37): 51, 1979

Grid pricing versus average pricing for fed cattle: an empirical analysis. Proceedings Western Agricultural Economics Association, Selected Papers of the 1999 Annual Meeting, Fargo, North Dakota, USA, 11-14 July 1999: 21 pp., 1999

Pricing Timberland Assets in the United States by the Arbitrage Pricing Theory. Forest Science 60(5): 943-952, 2014

Pricing efficiency of the Malaysian vegetable market: testing for asymmetric pricing. Journal of International Food and Agribusiness Marketing 7(4): 59-76, 1995

Drug Pricing Information Management: Development Of A Web Based E-Pricing System. Value in Health 18(7): A537-A538, 2015

Value-Based pricing and the end of pharmaceutical pricing as we know it? A case study on sorafenib and axitinib. Pharmacological Research 124: 160-163, 2017